Detalhe da pesquisa
1.
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Blood
; 140(2): 112-120, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35427411
2.
Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
Am J Hematol
; 99(4): 780-784, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357757
3.
Pitfalls of Current Diagnostic Criteria of Tumor Lysis Syndrome.
Kidney Blood Press Res
; 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38471470
4.
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Blood
; 137(24): 3327-3338, 2021 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33786588
5.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Blood
; 138(26): 2810-2827, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407545
6.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259589
7.
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
N Engl J Med
; 381(5): 432-443, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31365801
8.
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Blood
; 135(15): 1204-1213, 2020 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31876911
9.
How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?
Curr Oncol Rep
; 24(12): 1705-1713, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36334220
10.
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Blood
; 133(19): 2031-2042, 2019 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30842083
11.
Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins.
J Immunol
; 202(10): 2924-2944, 2019 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30988120
12.
Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.
J Immunol
; 201(5): 1570-1585, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30068596
13.
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med
; 374(4): 323-32, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26641137
14.
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Blood
; 129(16): 2224-2232, 2017 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28167659
15.
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood
; 129(19): 2612-2615, 2017 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28373262
16.
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
Blood
; 129(5): 553-560, 2017 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27903528
17.
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
Am J Hematol
; 94(5): 554-562, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30767298
18.
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Am J Hematol
; 94(12): 1353-1363, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31512258
19.
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Health Qual Life Outcomes
; 17(1): 173, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31729982
20.
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol
; 18(3): 297-311, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28139405